Akriveia Therapeutics’ focus is on the treatment of cancer.

There is a clear and urgent medical need for safer and more efficacious immunotherapeutics, in particular for medicines that can be administered in combinations that would otherwise be too toxic.

Akriveia is able to leverage its ability to create "best-in-class" therapeutics to focus on molecular targets that have already been shown to produce a clear clinical benefit.

In addition, Akriveia Therapeutics’ platform allows the company to address molecular targets that would otherwise result in prohibitively high toxicity with today’s standard biomolecular formats.

Copyright © 2016 Akriveia Therapeutics / All rights reserved.